Abstract 2629: Single and combined inhibition of PAK and Hippo pathway in NF2-deficient schwannoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2629
Abstract: Neurofibromatosis 2 (NF2) Syndrome is a rare, but devastating genetic condition that leads to non-cancerous tumors of the nervous system. NF2 patients are likely to develop Schwannomas on the eighth cranial nerve that lead to… read more here.
Keywords: schwannoma; inhibition; nf2 deficient; hippo ... See more keywords
Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma
Sign Up to like & getrecommendations! Published in 2024 at "PLOS ONE"
DOI: 10.1371/journal.pone.0305121
Abstract: Neurofibromatosis type 2 is a genetic disorder that results in the formation and progressive growth of schwannomas, ependymomas, and/or meningiomas. The NF2 gene encodes the Merlin protein, which links cell cortical elements to the actin… read more here.
Keywords: inhibitor; hippo pathway; nf2 deficient;
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24112
Abstract: Papillary renal cell carcinomas (PRCC) are a histologically and genetically heterogeneous group of tumors that represent 15–20% of all kidney neoplasms and may require diverse therapeutic approaches. Alteration of the NF2 tumor suppressor gene, encoding… read more here.
Keywords: hippo signaling; prcc; nf2 deficient; signaling pathway ... See more keywords